亚宝药业(600351.SH)：ZY-A002获得药物临床试验批准通知书

Core Viewpoint - The company, Yabao Pharmaceutical (600351.SH), has received approval from the National Medical Products Administration for the clinical trial of ZY-A002, aimed at treating children with cough variant asthma [1] Group 1: Company Information - Yabao Pharmaceutical has been granted a clinical trial approval notice (No. 2025LP02459) for ZY-A002 [1] - ZY-A002 is indicated for the treatment of cough variant asthma in children, characterized by symptoms such as coughing, throat itching, and minimal sputum production [1] Group 2: Industry Context - The approval of ZY-A002 represents a significant step in addressing pediatric respiratory conditions, particularly cough variant asthma, which is a growing concern in the healthcare sector [1]